Synonym
RB394; RB 394; RB-394;
IUPAC/Chemical Name
2-(4-((4-methoxy-2-(trifluoromethyl)benzyl)carbamoyl)benzyl)butanoic acid
InChi Key
JUYLDNKPEWYVEB-UHFFFAOYSA-N
InChi Code
InChI=1S/C21H22F3NO4/c1-3-14(20(27)28)10-13-4-6-15(7-5-13)19(26)25-12-16-8-9-17(29-2)11-18(16)21(22,23)24/h4-9,11,14H,3,10,12H2,1-2H3,(H,25,26)(H,27,28)
SMILES Code
COC1=CC(C(F)(F)F)=C(CNC(C2=CC=C(CC(C(O)=O)CC)C=C2)=O)C=C1
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, DMF, and ethanol
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO, DMF, and ethanol
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
RB394 is an orally bioavailable, dual modulator of soluble epoxide hydrolase (sEH) and PPARγ that inhibits sEH with an IC50 of 0.33 µM and activates PPARγ with an EC50 of 0.3 µM. It is inactive at PPARδ and shows 29% activation of PPARα, relative to control, at 10 µM. RB394 is water soluble, orally bioavailable, and can be delivered through drinking water.
In vitro activity:
To be determined
In vivo activity:
RB394 can attenuate renal fibrosis in a mouse unilateral ureteral obstruction model by reducing renal inflammation, oxidative stress, tubular injury, and vascular injury. RB394 demonstrates exciting potential as a therapeutic for renal fibrosis and chronic kidney disease.
Reference: Prostaglandins Other Lipid Mediat. 2020 Oct;150:106472. https://pubmed.ncbi.nlm.nih.gov/32569747/
|
Solvent |
mg/mL |
mM |
| Solubility |
| DMSO |
33.0 |
80.60 |
| DMF |
25.0 |
61.06 |
| Ethanol |
5.0 |
12.21 |
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
409.41
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
1. Hartmann M, Bibli SI, Tews D, Ni X, Kircher T, Kramer JS, Kilu W, Heering J, Hernandez-Olmos V, Weizel L, Scriba GKE, Krait S, Knapp S, Chaikuad A, Merk D, Fleming I, Fischer-Posovszky P, Proschak E. Combined Cardioprotective and Adipocyte Browning Effects Promoted by the Eutomer of Dual sEH/PPARγ Modulator. J Med Chem. 2021 Mar 11;64(5):2815-2828. doi: 10.1021/acs.jmedchem.0c02063. Epub 2021 Feb 23. PMID: 33620196.
2. Stavniichuk A, Hye Khan MA, Yeboah MM, Chesnik MA, Jankiewicz WK, Hartmann M, Blöcher R, Kircher T, Savchuk O, Proschak E, Imig JD. Dual soluble epoxide hydrolase inhibitor/PPAR-γ agonist attenuates renal fibrosis. Prostaglandins Other Lipid Mediat. 2020 Oct;150:106472. doi: 10.1016/j.prostaglandins.2020.106472. Epub 2020 Jun 20. PMID: 32569747.
3. Hye Khan MA, Kolb L, Skibba M, Hartmann M, Blöcher R, Proschak E, Imig JD. A novel dual PPAR-γ agonist/sEH inhibitor treats diabetic complications in a rat model of type 2 diabetes. Diabetologia. 2018 Oct;61(10):2235-2246. doi: 10.1007/s00125-018-4685-0. Epub 2018 Jul 21. PMID: 30032428; PMCID: PMC6563928.
In vitro protocol:
To be determined
In vivo protocol:
1. Hartmann M, Bibli SI, Tews D, Ni X, Kircher T, Kramer JS, Kilu W, Heering J, Hernandez-Olmos V, Weizel L, Scriba GKE, Krait S, Knapp S, Chaikuad A, Merk D, Fleming I, Fischer-Posovszky P, Proschak E. Combined Cardioprotective and Adipocyte Browning Effects Promoted by the Eutomer of Dual sEH/PPARγ Modulator. J Med Chem. 2021 Mar 11;64(5):2815-2828. doi: 10.1021/acs.jmedchem.0c02063. Epub 2021 Feb 23. PMID: 33620196.
2. Stavniichuk A, Hye Khan MA, Yeboah MM, Chesnik MA, Jankiewicz WK, Hartmann M, Blöcher R, Kircher T, Savchuk O, Proschak E, Imig JD. Dual soluble epoxide hydrolase inhibitor/PPAR-γ agonist attenuates renal fibrosis. Prostaglandins Other Lipid Mediat. 2020 Oct;150:106472. doi: 10.1016/j.prostaglandins.2020.106472. Epub 2020 Jun 20. PMID: 32569747.
3. Hye Khan MA, Kolb L, Skibba M, Hartmann M, Blöcher R, Proschak E, Imig JD. A novel dual PPAR-γ agonist/sEH inhibitor treats diabetic complications in a rat model of type 2 diabetes. Diabetologia. 2018 Oct;61(10):2235-2246. doi: 10.1007/s00125-018-4685-0. Epub 2018 Jul 21. PMID: 30032428; PMCID: PMC6563928.
1: Hartmann M, Bibli SI, Tews D, Ni X, Kircher T, Kramer JS, Kilu W, Heering J, Hernandez-Olmos V, Weizel L, Scriba GKE, Krait S, Knapp S, Chaikuad A, Merk D, Fleming I, Fischer-Posovszky P, Proschak E. Combined Cardioprotective and Adipocyte Browning Effects Promoted by the Eutomer of Dual sEH/PPARγ Modulator. J Med Chem. 2021 Feb 23. doi: 10.1021/acs.jmedchem.0c02063. Epub ahead of print. PMID: 33620196.
2: Stavniichuk A, Hye Khan MA, Yeboah MM, Chesnik MA, Jankiewicz WK, Hartmann M, Blöcher R, Kircher T, Savchuk O, Proschak E, Imig JD. Dual soluble epoxide hydrolase inhibitor/PPAR-γ agonist attenuates renal fibrosis. Prostaglandins Other Lipid Mediat. 2020 Oct;150:106472. doi: 10.1016/j.prostaglandins.2020.106472. Epub 2020 Jun 20. PMID: 32569747.
3: Hye Khan MA, Kolb L, Skibba M, Hartmann M, Blöcher R, Proschak E, Imig JD. A novel dual PPAR-γ agonist/sEH inhibitor treats diabetic complications in a rat model of type 2 diabetes. Diabetologia. 2018 Oct;61(10):2235-2246. doi: 10.1007/s00125-018-4685-0. Epub 2018 Jul 21. PMID: 30032428; PMCID: PMC6563928.
